anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled crude drug without causing the degradation of the gall component, by denaturating the protein component of an animal gall with acetone, etc., or by acidifying the gall with glacial acetic acid, etc., thereby removing or inactivating the enzyme, etc., existing slightly in the gall. CONSTITUTION:The protein component existing in an animal gall (e.g. obtained from the cattle gallbladder, swine gallbladder, etc.) is denaturated with acetone or alcohol, or the gall is acidified (to about 3.0-4.0pH) with an acid such as glacial acetic acid or citric acid, etc. to effect the denaturation and inactivation of the enzymatic activity. The protein component is removed by filtration or centrifugal separation, and the residual gall is concentrated in vacuum and then freeze-dried to obtain the objective crude drug consisting of odorless and dried animal gall.
A noninvasive method of determining function of a target organ using a pre-calibrated imaging system is described. The method contains the steps of introducing an indicator/tracer bolus into the subject's circulatory system and thereafter monitoring simultaneously the responses recorded from the heart/great vessels, and from the target organ. The absolute activity per unit volume of blood withdrawn at a known time(s) is measured, and the observed data from the heart or great vessels is converted into absolute units. These data serve as B(t), the input function. Precalibration of the detector/measuring system allows the observed dynamic indicator/tracer data recorded from the target organ to be expressed in units of absolute activity. These data serve as A(t). A(t) and B(t) are deconvolved in order to obtain the linear response function (LRF, h(t)) for an image element. A preferred method of deconvolution, the DOP method is introduced. Functional images of the target organ's LRF are created.
The present invention relates to deodorant compositions comprising morpholino compounds and their use in preventing or reducing body odour. Also provided is a method of reducing or preventing body odour. A preferred compound is 3-(4-propyl-heptyl)-4-(2-hydroxyethyl) morpholine, i.e. delmopinol. The composition may further comprise an antimicrobial agent, in particular an antibiotic e.g. triclosan, propyl-p-hydroxybenzoate, chlorhexidine gluconate, sodium lactoyl caprylate, trichlorocarbonilide, zinc undecylenate or glycerolether.
The invention relates to medicine, in particular to pharmaceutical compositions for long acting tablets and to production methods thereof. The inventive pharmaceutical composition comprises microcapsules of a medicinal substance 96.0-99.2 mass %, a lubricant 0.1-1.0 mass %, water 0.1-3 mass % and an expander 0.1-1.0 mass % with respect to total mass of a mixture. Each microcapsule comprises the medicinal substance (96.0-99.2 mass %) and a film-forming material (0.8-4.0 mass %). The inventive method consists in producing the microcapsules by applying envelopes made of the film forming material to nonaglomerated particles of the medicinal substance and adding the lubricant and the expander. The moisture of the envelope is equal to or less than 0.5 mass %. Prior to adding the lubricant and the expander, the microcapsules are moisturised in order to obtain a moisture of 0.1-3 mass %. The lubricant being introduced into the mixture, the expander is added in the form of a cut fraction of the medicinal substance.
The study is a randomized, unblinded, prospective, single center clinical trial. The purpose of the study is to determine the effect of a music intervention in reducing anxiety and pain from local anesthesia administration in subjects undergoing a routine, standard of care dermatologic procedure. The study population will consist of 100 adult subjects undergoing a dermatologic procedure on the head and neck. Subjects will be randomized 1:1 into either the placebo or music intervention group.

Individuals randomized into the placebo (P) group will undergo a set of standardized steps prior to local anesthesia injection. Other factors such as skin preparation technique, needle size, anesthesia temperature, use of unbuffered solution, needle angle and approximate depth of injection will remain standardized. Individuals randomized into the music intervention (MI) group will undergo the same set of standardized steps and then be played Frederic Chopin's piano sonatas through a headphone device prior to injection. After local anesthesia administration, subjects in both treatment arms will be asked to fill out a demographics, pain and anxiety questionnaire.
BACKGROUND: Tuberculous peritonitis often presents with nonspecific symptoms that can lead to diagnostic challenges, particularly when manifesting as peritoneal pseudocysts. This study highlights the clinical complexity and diagnostic approach of tuberculous peritonitis presented as a pseudocyst in an immunocompetent adult, an atypical scenario that is rarely documented.
CASE PRESENTATION: We report a detailed case of a 41-year-old man presenting with abdominal distension, pain, and significant weight loss over four months. Abdominal CT showed a peritoneal pseudocyst, initially misdiagnosed due to its resemblance to more common abdominal pathologies. The diagnosis of tuberculous peritonitis was confirmed through histopathological analysis. Additionally, a systematic literature review was conducted to identify and analyse similar cases, focusing on clinical presentations, diagnostic methods, and patient outcomes. Our patient exhibited classic symptoms of abdominal TB but was unique due to the absence of prior ventriculoperitoneal shunting, a common factor in similar cases. Our literature review found that such presentations typically result in diagnostic delays averaging five months, complicating patient management and outcomes. This review also underscores the importance of considering tuberculosis in the differential diagnosis of peritoneal pseudocysts, particularly in TB-endemic regions.
CONCLUSION: This case and review emphasize the need for high clinical suspicion and prompt investigation of tuberculosis in patients presenting with atypical abdominal symptoms and pseudocysts. Improved diagnostic strategies, including early use of imaging and pathological evaluations, are essential for timely diagnosis and management, thereby improving patient outcomes in suspected cases of extrapulmonary tuberculosis.
Osteoarthritis (OA) is a common chronic condition, characterized by progressive loss of joint cartilage, leading to joint pain, stiffness, and functional disability. Knee OA is one of the most prevalent forms of OA, affecting millions of people worldwide. Various non-surgical treatment options have been reported, one of them is taping techniques. Combination taping is a unique treatment option, where two different types of taping is applied. However, there is limited research on the effects of combination taping techniques on disability, functional capacity, and knee isokinetic torque in patients with knee OA. So this study will be conducted to explore therapeutic effects in individuals who are suffering from knee OA
Patients should be informed of the possibility of adverse reactions and of the need for careful medical supervision. The occurrence of sore throat, fever, pallor, purpura, or jaundice may indicate a serious blood disorder. Should any of these occur, the patient should seek medical advice. They should also be made aware that ulcerative colitis rarely remits completely, and that the risk of relapse can be reduced by continued administration of AZULFIDINE at a maintenance dosage. Patients should be instructed to take AZULFIDINE in evenly divided doses preferably after meals. Additionally, patients should be advised that sulfasalazine may produce an orange-yellow discoloration of the urine or skin.
PURPOSE:To provide the titled composition containing the pigment component of crude sugar as an essential component. CONSTITUTION:The objective external composition for dermatitis can be pro duced by compounding (A) 100-10,000mg, preferably 5,000 mg of the pigment component of crude sugar (yellowish brown sugar produced by squeezing sugar cane and subjecting the sugar juice to cleaning, concentration, crystallization, curing, etc.), e.g. the compound of formula I, compound of formula II, etc., with (B) 50g of cosmetic cream or 100g of toilet soap. The pigment component can be produced by dissolving crude sugar in a proper amount of water, treating the solution with an adsorbent to effect the adsorption of the pigment component to the adsorbent, washing the adsorbent with water, removing the sugar compo nent completely from the adsorbent, and eluting the adsorbed pigment component with a solvent. EFFECT:Effective to cure dermatitis of obesity patient. It can be produced at an extremely low cost utilizing the hitherto discarded pigment component of crude sugar.
Background: Obesity has reached epidemic proportions, and often has serious adverse health consequences. The VA has deployed a "MOVE! Weight Management Program" nationally in the general patient population. Since individuals with serious mental illness (SMI) often have cognitive deficits, specialized psychoeducational interventions are needed in this population. Specialized psychoeducational interventions for weight have been developed and studied in populations with SMI. This evidence-based practice has been adapted for use in VA, resulting in a "MOVE! SMI" intervention. However, it has proven to be quite difficult to disseminate this intervention. Patients with SMI often have limited transportation options, and may not want to participate in groups. Also, in-person MOVE! SMI requires substantial time from mental health clinicians. This clinician time has been difficult to deploy or is not available at many clinic locations. It is likely that these barriers can be addressed with a computerized, web-based version of MOVE! . Specialized web-based approaches have been studied and found to be successful in people with SMI, and can deliver content that is intensive and engaging with minimal requirements for staff time.

Objectives: The VA Network 5 and 22 Mental Illness Research, Education, and Clinical Centers (MIRECCs) developed a web-based system that provides computerized counseling regarding diet to individuals with SMI. The proposed project expanded this system. This project's objectives are to: 1) develop a comprehensive web-based system that delivers MOVE! using design features that meet the needs of individuals with mental illness; 2) evaluate the effectiveness, in patients with serious mental illness, of web-based MOVE! compared with in-person MOVE! and a control group; and, 3) characterize, from the patient's perspective, the strengths, weaknesses, and barriers to the use of in-person and web-based MOVE!.

Methods: This is a prospective, randomized, controlled trial in patients with SMI who are obese and receiving treatment with medications that often have weight gain as a major side-effect. Participants are assigned to in-person MOVE! SMI, web-based MOVE! SMI with support from peer coaches, or a comparison group. Research assessments occur at 0, 3, 6, 9 and 12 months. Changes in outcomes are compared over time between the three groups. Comparative effectiveness is evaluated at 6 months. A secondary objective is to evaluate the extent to which gains are maintained at 9 and 12 months.

Status: The project team developed the needed materials, methods, and informatics systems. Patients were enrolled, and study enrollment and interventions are complete. Follow up interviews are complete and the interventions have been evaluated.
The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. A refreshment training will be introduced at month 11.
In the implementation of the experimental group, hippotherapy implementation consisting of a total of 5 stations created by the researchers, lasting 30 minutes individually, will be applied to the individuals in the intervention group for 8 weeks, with the participation of the riding coaches. Research data will be collected by the researchers before the implementation (0th), in the 4th and 8th weeks.
There have been many biomarkers, such as angiogenesis factors and cytokines, related to cancer progression or microenvironment interaction. However, the commonly used enzyme-linked immunosorbent assay (ELISA) requires the certain volume of each sample for specific antigen or antibody. It may not be practically efficient to test a broad spectrum of biomarkers with limited volumes of serum from cancer patients. Proximity ligation assay (PLA), an established concept and platform requiring very little sample volume to quantitatively detect a variety of biomarkers, is being developed with multiplex versions of improved sensitivity and dynamic range by the Stanford group. From the three completed trials ("In vivo/vitro radiation-induced liver disease in HBV carrier（9261700196）", "Bystander effect study of radiation-induced viral hepatitis B reactivation（9261700196）", and "Pre- and post-chemoradiation blood RNA-microarray analysis to predict response and outcome of locally advanced esophageal squamous cell carcinoma（200805061R）") and one ongoing trial ("A phase I dose escalation trial of conformal hypofractionated radiation therapy for patients with hepatitis B virus-related Child A cirrhosis and hepatocellular carcinoma（200906051R）"), we have collected the pre-treatment and post-treatment serum samples of patients with hepatocellular carcinoma undergoing definitive radiotherapy and patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy. Altered patterns of failure for post-radiotherapy hepatocellular carcinoma, especially intrahepatic and extrahepatic metastasis, and treatment response for post-chemoradiotherapy esophageal cancer upon esophagectomy, demands the effective biomarkers for the early prediction and appropriate management. The limited sample volumes form the obstacle of testing adequate number of biomarkers by ELISA. In this study we plan to collaborate with the Stanford group, to send and process these samples (100 μL each) to measure the dynamic changes of up to 56 or more biomarkers. We try to find the potential biomarkers correlating with treatment responses and patterns of failure for the future clinical practice, and wish to set up this viable PLA platform in our institute through this collaboration.
A composition comprising lactic acid bacteria that are selected from at least one of  Lactococcus lactis, Lactobacillus lactis,  and  Lactobacillus brevis.  The composition is suitable for administration to animals. Upon administration to an animal, the composition provides at least one of the following (a) improves performance in the animal and (b) reduces scours in animals. Also provided is a method of treating an animal in which the composition is administered to the animal. A method of forming a direct-fed microbial is also provided. A culture including the lactic acid bacteria is grown in a liquid nutrient broth. The lactic acid bacteria are separated from the liquid nutrient broth. The lactic acid bacteria can be freeze dried.
Sensorimotor control involves the integration of sensory information in the brain to ensure appropriate joint position, force control and timing during movement. Kinesio taping can provide additional sensory input and improve sensorimotor control performance. Hand function is important in daily activities and fine control of the fingers and wrist is required in many sports. Therefore, we explore the effect of Kinesio taping with different tension on hand force control, joint proprioception, reaction time and brain activity.

This is an observational study with single-group repeated-measures design. Participants will be randomly received three wrist/finger flexor taping conditions: (1) taping with 20% additional tension (taping20), (2) taping with neutral tension (tapingN), and (3) without taping (control). Grip force, wrist joint angle, electroencephalogram and electromyogram were recorded during proprioception and force control tasks.Repeated-measures one-way analysis of variance and the Bonferroni post hoc comparison test determined the differences among the taping conditions. The Pearson correlation test determined the correlation between changes in motor performance and brain activities. Statistical significance was set at .05.
The investigators recruited male subjects admitted to who met the criteria. They were divided into a control and a treatment group. A double-blind approach was adopted. The subjects were unaware of whether real/pseudo stimulation was applied, and the evaluators did not know the grouping specifics. All of the enrolled cases were tested for stimulation thresholds in the bilateral prefrontal cortex. The TMS treatment device was a Magstim RAPID2 neuromagnetic stimulator (Magstim) with an "8"-type coil. The study group was administered real stimulation. The treatment parameters were as follows: frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. For the control group, a 60% motion threshold was set; the remaining parameters were consistent with the study group but with no stimulating energy output. The therapeutic instrument model, appearance, operation process, and sounds when effecting treatment were the same for both groups. A self-experience checklist post-TMS treatment and positive and negative symptom scales (PANSS) were applied to evaluate the treatment.
Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
The hypothesis is that multiparametric models that incorporate complex image information from screening CT scans will improve prediction of the outcome of subsequent lung biopsy, an invasive diagnostic procedure. In this project, we will construct an image feature-based multiparametric prognostic model for biopsy outcome from screening lung CT scans performed at our institution, and then validate it using theNLST imaging and clinical outcomes dataset.

This study involves no treatment or invasive procedures. Investigator will review all charts of patients who were treated for early stage lung cancer with definitive radiation therapy at UTSW or Parkland Memorial hospital, diagnosed with a malignancy from January 1, 2004 to October 31, 2014, to compile demographic, diagnostic, therapeutic, outcome, and toxicity data. Investigator expect that this will include approximately 200 patient charts. This data will be analyzed statistically and used for future directed research. Investigator will also analyze an anonymized dataset of patients from the National Lung Cancer Screening Trial (NLST) provided by the National Cancer Institute (NCI)
This is a randomized, double-blind, placebo-controlled Phase IIa clinical trial to test the efficacy and safety of CORT108297- 180mg daily for 7 days for PTSD symptoms in Veterans. Each of the two sites will enroll 44 Veterans with chronic PTSD. Participants first will undergo screening procedures, including a clinical psychological interview, self-report questionnaires, blood draw, and medical evaluations. If eligible, they will be randomized to either CORT108297 or placebo. The same procedures will be repeated at several in-person and virtual visits before, during and after taking the study drug or placebo for seven days. The key outcome measures will be obtained at baseline, day 7, 28, and day 56.

There is large body of evidence demonstrating that Posttraumatic Stress Disorder (PTSD) is associated with alterations in the stress hormone cortisol. There is also evidence that medications that block cortisol may be beneficial for treating PTSD and depression. This study will test a medication, CORT108297, which is from a new class of cortisol blockers which have no effect on other hormones. CORT108297 has been shown to have efficacy in preclinical CNS models and was well tolerated and safe in Phase I healthy volunteer studies making it a candidate for further development. Thus, the goal will be to complete a Phase IIa proof of concept trial of CORT108297 to focus on safety and tolerability and obtain pilot efficacy data to inform the design of future clinical trials.
Cutaneous plaques and squamous cell carcinoma (SCC) are common in captive North American snow leopards (SLs) (Panthera uncia). Our objective was to determine whether these lesions are potentially associated with papillomavirus(es). Polymerase chain reaction (PCR) was performed on 3 cutaneous plaques using degenerate primers for papillomaviruses. A putatively novel papillomavirus was identified that shared 76% sequence identity to Felis catus papillomavirus 2. Specific PCR for this virus was performed on 5 cutaneous SCC samples and 7 normal skin samples, which were all positive. In situ hybridization for this putatively novel virus was performed, which revealed strong hybridization signals within hyperplastic cells in cutaneous plaques (n = 3) and within neoplastic cells in cutaneous SCC samples (n = 5). No hybridization signals were identified within normal skin. Ultimately, identification of a causal viral agent in the development of plaques and SCC in SLs will help guide therapeutic intervention and lay the foundation for development of prophylactic vaccines.
A multi-center, open-label, prospective cohorts study. Patients with a regular indication for COH/IUI (controlled ovarian stimulation/ intra uterine insemination) will be asked to participate. Patient's characteristics will be documented including age, weight, BMI, smoking status, cycle day 2 3 or 4 FSH /Estradiol levels, antral follicle count, and AMH. AMH and FSH/Estradiol will be determined centrally after completion of inclusion of all patients in the study. All patients will receive a fixed 75 IU recFSH per day conform normal stimulation protocol starting from cycle day 3, 4 or 5 after exclusion of ovarian cysts by ultrasound. Ovarian response will be documented by ultrasound only. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Cancellation criteria will be defined according to the national guidelines provided by the NVOG (7).